Literature DB >> 24163006

Natural compounds with P2X7 receptor-modulating properties.

Wolfgang Fischer1, Nicole Urban, Kerstin Immig, Heike Franke, Michael Schaefer.   

Abstract

The adenosine 5'-triphosphate (ATP)-gated P2X7 receptor is a membrane-bound, non-selective cation channel, expressed in a variety of cell types. The P2X7 senses high extracellular ATP concentrations and seems to be implicated in a wide range of cellular functions as well as pathophysiological processes, including immune responses and inflammation, release of gliotransmitters and cytokines, cancer cell growth or development of neurodegenerative diseases. In the present study, we identified natural compounds and analogues that can block or sensitize the ATP (1 mM)-induced Ca(2+) response using a HEK293 cell line stably expressing human P2X7 and fluorometric imaging plate reader technology. For instance, teniposide potently blocked the human P2X7 at sub-miromolar concentrations, but not human P2X4 or rat P2X2. A marked block of ATP-induced Ca(2+) entry and Yo-Pro-1 uptake was also observed in human A375 melanoma cells and mouse microglial cells, both expressing P2X7. On the other hand, agelasine (AGL) and garcinolic acid (GA) facilitated the P2X7 response to ATP in all three cell populations. GA also enhanced the YO-PRO-1 uptake, whereas AGL did not affect the ATP-stimulated intracellular accumulation of this dye. According to the pathophysiological role of P2X7 in various diseases, selective modulators may have potential for further development, e.g. as neuroprotective or antineoplastic drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24163006      PMCID: PMC4040168          DOI: 10.1007/s11302-013-9392-1

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  56 in total

1.  Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.

Authors:  Thomas C Stock; Bradley J Bloom; Nathan Wei; Saliha Ishaq; Won Park; Xin Wang; Pankaj Gupta; Charles A Mebus
Journal:  J Rheumatol       Date:  2012-03-01       Impact factor: 4.666

2.  The marine sponge toxin agelasine B increases the intracellular Ca(2+) concentration and induces apoptosis in human breast cancer cells (MCF-7).

Authors:  Adriana A Pimentel; Pimali Felibertt; Felipe Sojo; Laura Colman; Adriana Mayora; May Li Silva; Hector Rojas; Reinaldo Dipolo; Alírica I Suarez; Reinaldo S Compagnone; Francisco Arvelo; Ivan Galindo-Castro; Juan B De Sanctis; Perla Chirino; Gustavo Benaim
Journal:  Cancer Chemother Pharmacol       Date:  2011-05-21       Impact factor: 3.333

3.  Antimicrobial and antineoplastic activities of agelasine analogs modified in the purine 2-position.

Authors:  Heidi Roggen; Colin Charnock; Robert Burman; Jenny Felth; Rolf Larsson; Lars Bohlin; Lise-Lotte Gundersen
Journal:  Arch Pharm (Weinheim)       Date:  2010-11-25       Impact factor: 3.751

4.  CD14 and TRIF govern distinct responsiveness and responses in mouse microglial TLR4 challenges by structural variants of LPS.

Authors:  Tommy Regen; Denise van Rossum; Jörg Scheffel; Maria-Eleni Kastriti; Natalia H Revelo; Marco Prinz; Wolfgang Brück; Uwe-Karsten Hanisch
Journal:  Brain Behav Immun       Date:  2010-10-15       Impact factor: 7.217

5.  Synthesis, antimicrobial and antineoplastic activities for agelasine and agelasimine analogs with a beta-cyclocitral derived substituent.

Authors:  Agnes Proszenyák; Colin Charnock; Erik Hedner; Rolf Larsson; Lars Bohlin; Lise-Lotte Gundersen
Journal:  Arch Pharm (Weinheim)       Date:  2007-12       Impact factor: 3.751

6.  Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins.

Authors:  Dayong Zhai; Chaofang Jin; Chung-Wai Shiau; Shinichi Kitada; Arnold C Satterthwait; John C Reed
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

Review 7.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

8.  Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response.

Authors:  Jeffrey M Labasi; Nina Petrushova; Carol Donovan; Sandra McCurdy; Paul Lira; Mary M Payette; William Brissette; Joan R Wicks; Laurent Audoly; Christopher A Gabel
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

9.  Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists.

Authors:  Derek W Nelson; Kathy Sarris; Douglas M Kalvin; Marian T Namovic; George Grayson; Diana L Donnelly-Roberts; Richard Harris; Prisca Honore; Michael F Jarvis; Connie R Faltynek; William A Carroll
Journal:  J Med Chem       Date:  2008-04-26       Impact factor: 7.446

10.  Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.

Authors:  J H Rodman; W L Furman; M Sunderland; G Rivera; W E Evans
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

View more
  15 in total

1.  Functional P2X7 Receptors in the Auditory Nerve of Hearing Rodents Localize Exclusively to Peripheral Glia.

Authors:  Silvia Prades; Gregory Heard; Jonathan E Gale; Tobias Engel; Robin Kopp; Annette Nicke; Katie E Smith; Daniel J Jagger
Journal:  J Neurosci       Date:  2021-02-09       Impact factor: 6.167

2.  Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor.

Authors:  Jingjia Yan; Jiaxiao Sun; Zhiyuan Zeng
Journal:  Inflammopharmacology       Date:  2017-08-20       Impact factor: 4.473

3.  Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme.

Authors:  Kristen M Feibelman; Benjamin P Fuller; Linfeng Li; Daniel V LaBarbera; Brian J Geiss
Journal:  Antiviral Res       Date:  2018-04-20       Impact factor: 5.970

Review 4.  Involvement of P2 receptors in hematopoiesis and hematopoietic disorders, and as pharmacological targets.

Authors:  Kelly Juliana Filippin; Kamylla F S de Souza; Roberto Theodoro de Araujo Júnior; Heron Fernandes Vieira Torquato; Dhébora Albuquerque Dias; Eduardo Benedetti Parisotto; Alice Teixeira Ferreira; Edgar J Paredes-Gamero
Journal:  Purinergic Signal       Date:  2019-12-20       Impact factor: 3.765

5.  Genetically dissecting P2rx7 expression within the central nervous system using conditional humanized mice.

Authors:  Michael W Metzger; Sandra M Walser; Fernando Aprile-Garcia; Nina Dedic; Alon Chen; Florian Holsboer; Eduardo Arzt; Wolfgang Wurst; Jan M Deussing
Journal:  Purinergic Signal       Date:  2016-11-17       Impact factor: 3.765

Review 6.  To Inhibit or Enhance? Is There a Benefit to Positive Allosteric Modulation of P2X Receptors?

Authors:  Leanne Stokes; Stefan Bidula; Lučka Bibič; Elizabeth Allum
Journal:  Front Pharmacol       Date:  2020-05-12       Impact factor: 5.810

Review 7.  Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer.

Authors:  Matthew Drill; Nigel C Jones; Martin Hunn; Terence J O'Brien; Mastura Monif
Journal:  Purinergic Signal       Date:  2021-03-17       Impact factor: 3.765

8.  The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.

Authors:  Andrea Giannuzzo; Stine Falsig Pedersen; Ivana Novak
Journal:  Mol Cancer       Date:  2015-11-25       Impact factor: 27.401

9.  Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models.

Authors:  Wolfgang Fischer; Heike Franke; Ute Krügel; Heiko Müller; Klaus Dinkel; Brian Lord; Michael A Letavic; David C Henshall; Tobias Engel
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

Review 10.  Membrane Transporters and Channels in Melanoma.

Authors:  Ines Böhme; Roland Schönherr; Jürgen Eberle; Anja Katrin Bosserhoff
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.